GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting.

Aims: Glucagon-like peptide-1 (GLP-1) receptor agonists, alongside dual receptor agonists targeting glucose-dependent insulinotropic polypeptide (GIP) receptors, represent transformative therapies for obesity management. Despite their increasing use, patient perspectives of these treatments remain underexplored. This exploratory study aimed to examine the experiences and attitudes of individuals using GLP-1 medications (GLP-1s) for weight loss, focusing on motivators, barriers and reasons for discontinuation.

Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study.

Background: Biologic therapies have led to increasing numbers of patients with psoriasis who have clear or nearly clear skin. It is current practice to continue biologic therapy indefinitely in these patients, which contributes to a substantial long-term drug and healthcare burden. 'As needed' biologic therapy in psoriasis may address this; however, our understanding of patient and clinician perceptions of this strategy is limited.

Geroprotectors and Skeletal Health: Beyond the Headlines.

Osteoporosis and osteoarthritis are the most common age-related diseases of the musculoskeletal system. They are responsible for high level of healthcare use and are often associated with comorbidities. Mechanisms of ageing such as senescence, inflammation and autophagy are common drivers for both diseases and molecules targeting those mechanisms (geroprotectors) have potential to prevent both diseases and their co-morbidities.